A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2004 by Trimeris.
Recruitment status was  Active, not recruiting
Information provided by:
ClinicalTrials.gov Identifier:
First received: October 28, 2002
Last updated: June 23, 2005
Last verified: July 2004
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Condition Intervention Phase
HIV Infections
Drug: T-1249
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Trimeris:


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion T1249-102;
  • Currently failing a T-20 containing regimen

Exclusion Criteria:

  • Non-completion of T1249-102.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048217

United States, North Carolina
Durham, North Carolina, United States, 27707
Sponsors and Collaborators
  More Information

ClinicalTrials.gov Identifier: NCT00048217     History of Changes
Other Study ID Numbers: T1249-105 
Study First Received: October 28, 2002
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Trimeris:
Treatment Experienced

ClinicalTrials.gov processed this record on May 26, 2016